{* socialRegistration_signInButton *} The information is not intended as medical advice.Site is intended for CA residents. Please try again. In patients with angina, there were no clinically significant reductions in blood pressures (4/1 mmHg) or changes in heart rate (+0.3 bpm).In a double-blind, placebo-controlled clinical trial of 4 weeks duration in 50 patients, Norvasc therapy decreased attacks by approximately 4/week compared with a placebo decrease of approximately 1/week (p<0.01). {* acknowledgement_terms *} {* familyName *} Frequent blood pressure measurements are essential. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.Monitor for hypotension when sildenafil is co-administered with amlodipine Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin.

Once daily administration produced statistically significant placebo-corrected reductions in supine and standing blood pressures at 24 hours postdose, averaging about 12/6 mmHg in the standing position and 13/7 mmHg in the supine position in patients with mild to moderate hypertension. See below for a comprehensive list of adverse effects. Indicated for hypertension, to lower blood pressureLowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions5 mg/day PO initially; may be increased by 2.5 mg/day every 7-14 days; not to exceed 10 mg/day maintenance: 5-10 mg/dayTreatment of chronic stable angina, vasospastic angina (Prinzmetal or variant angina), and angiographically documented CAD in patients without heart failure or EF <40%5-10 mg/day PO initially; maintenance: 10 mg/day POStart dosing at low end of dosing range; elderly patients have greater frequency of decreased renal, hepatic or cardiac function2.5-5 mg/day PO initially; may be increased by 2.5 mg/day every 7-14 days; not to exceed 10 mg/day PO; maintenance: 5-10 mg/day POTreatment of chronic stable angina, vasospastic angina (Prinzmetal or variant angina), and angiographically documented CAD in patients without heart failure or EF <40%2.5-10 mg/day PO initially; maintenance: 10 mg/day POCardiovascular: Arrhythmia (eg, ventricular tachycardia, atrial fibrillation), bradycardia, chest pain, peripheral ischemia, syncope, tachycardia, vasculitisCentral and peripheral nervous system: Hypoesthesia, neuropathy peripheral, paresthesia, tremor, vertigoGastrointestinal: Anorexia, constipation, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasiaGeneral: Allergic reaction, asthenia, back pain, hot flushes, malaise, pain, rigors, weight gain, weight decreaseMusculoskeletal system: Arthralgia, arthrosis, muscle cramps, myalgiaPsychiatric: Sexual dysfunction (male and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalizationSkin and appendages: Angioedema, erythema multiforme, pruritus, rash, rash erythematous, rash maculopapularSpecial senses: Abnormal vision, conjunctivitis, diplopia, eye pain, tinnitusUrinary system: Micturition frequency, micturition disorder, nocturiaAutonomic nervous system: Dry mouth, sweating increasedPulmonary edema (higher incidence in heart failure patients)Jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis)Symptomatic hypotension is possible, particularly with severe aortic stenosis; owing to gradual onset of action, acute hypotension unlikelyWorsening of angina and acute myocardial infarction (MI) can develop after dose is started or increased, particularly with severe obstructive CADExtensively metabolized by the liver and plasma elimination half-life is 56 hr in patients with hepatic impairment; titrate slowly when treating patients with severe hepatic impairmentLimited available data based on postmarketing reports are insufficient to inform a drug-associated risk for major birth defects and miscarriage during pregnancyLimited available data from a published clinical lactation study reports that amlodipine is present in human milk at an estimated median relative infant doseNo adverse effects of amlodipine on breastfed infant reportedThere is no available information on effects of amlodipine on milk productionA: Generally acceptable. {* createAccountButton *} Select one or more newsletters to continue. {* acknowledgement_terms *} Limit the dose of simvastatin in patients on amlodipine to 20 mg daily Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Hypersensitivity. 4 CONTRAINDICATIONS . Please try again. WebMD provides common contraindications for Norvasc Oral. NORVASC (amlodipine besylate) is contraindicated in patients with hypersensitivity to the drug or other dihydropyridines* and in patients with severe hypotension (less than 90 mmHg systolic).

{* license_number *} Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. * Amlodipine besylate is a dihydropyridine calcium channel blocker. All material on this website is protected by copyright, Copyright © 1994-2020 by WebMD LLC.

Contraindications. Your login attempt failed.

Norvasc is contraindicated in patients with known sensitivity to amlodipine. To access full product monograph,